Petra Kienle News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Petra kienle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Petra Kienle Today - Breaking & Trending Today

Boehringer Ingelheim: CHMP recommends conditional marketing authorization for Spesolimab as first in class treatment option for generalized pustular psoriasis flares

CHMP positive opinion is based on evidence from the EFFISAYIL 1 trial, the largest clinical trial in patients with generalized pustular psoriasis (GPP) flares1 GPP is a rare and potentially ....

France General , Petra Kienle , Carinne Brouillon , Global Consensus Delphi Panel , Corporate Communications , Boehringer Ingelheim , European Medicine Agency , Medicinal Products , Human Use , Saint Louis University Hospital , Managing Directors , Human Pharma ,

U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults

Press release content from Business Wire. The AP news staff was not involved in its creation. ....

New York , United States , Rheinland Pfalz , Petra Kienle , Carinne Brouillon , Mark Lebwohl , Ericj Waldman Department Of Dermatology , Icahn School Of Medicine At Mount Sinai , Corporate Communications , Drug Administration , European Medicines Agency , Boehringer Ingelheim , Clinical Therapeutics , Icahn School , Mount Sinai , Managing Directors , Human Pharma , Breakthrough Therapy Designation , Priority Review , Orphan Drug Designation , Rare Disease Designation , Business Wire ,

Boehringer Ingelheim: U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults

Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares After ....

New York , United States , Petra Kienle , Carinne Brouillon , Mark Lebwohl , Ericj Waldman Department Of Dermatology , Icahn School Of Medicine At Mount Sinai , Corporate Communications , European Medicines Agency , Boehringer Ingelheim , Drug Administration , Clinical Therapeutics , Icahn School , Mount Sinai , Managing Directors , Human Pharma , Breakthrough Therapy Designation , Priority Review , Orphan Drug Designation , Rare Disease Designation ,